Nicotinamide Reduces Skin Cancer Risk – Veteran Study

Here’s a breakdown of the key facts from ⁣the provided text,focusing on the study and findings regarding nicotinamide and skin cancer:

Key Findings:

* Reduced ⁢Skin Cancer Risk: nicotinamide use was associated‍ with a 14% reduction in new skin cancers compared to a control group.
* Stronger⁢ Effect with Early Use: the protective effect‍ was most meaningful when nicotinamide supplementation started after a⁢ first skin cancer diagnosis, showing ⁢a 54% reduction⁤ in risk. The benefit lessened with multiple prior cancers.
* Consistency with Previous Research: ‍ The study’s results align with previous estimates (30-50% risk reduction) from earlier studies, including a phase 3 trial from 2015.
* ‍ Large Sample Size: This study included a ⁣larger sample size than many previous studies, strengthening it’s findings.

Study Details:

* Type: Real-world, retrospective observational study. (Critically important note: Observational studies cannot prove⁣ causation,only show association.)
* Participants: Over 12,000 veterans prescribed nicotinamide 500mg twice daily for at least 30 days, matched with over 21,000 unexposed controls.
* Data Source: Veterans Affairs Corporate Data⁣ Warehouse.
* Matching Factors: Participants were matched ⁤based on prior skin cancer history, age, race, field therapy exposure, and solid organ transplant status.
* Future Research: The authors plan a prospective clinical trial to confirm thes findings.

Background on Nicotinamide:

* It’s a form of vitamin B3 (niacin) that doesn’t cause flushing (a common side effect of niacin).
* It’s being studied for its potential to support DNA repair and reduce immune suppression caused by ultraviolet radiation.
*⁢ A 2015 phase 3 trial showed reduced skin cancer rates with nicotinamide use in patients with prior⁣ disease, leading to its recommendation by many dermatologists.